Sciencast Management LP bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,083 shares of the company's stock, valued at approximately $243,000.
Other large investors have also modified their holdings of the company. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $30,000. Kentucky Trust Co acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $33,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co grew its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.
Insider Activity
In other news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by corporate insiders.
Cencora Stock Up 1.1 %
Cencora stock traded up $2.94 during mid-day trading on Thursday, reaching $274.33. 1,015,455 shares of the company's stock were exchanged, compared to its average volume of 1,379,449. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $274.80. The company has a market cap of $53.20 billion, a P/E ratio of 39.02, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a fifty day moving average of $252.47 and a 200-day moving average of $240.68.
Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.
Analysts Set New Price Targets
Several research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $280.20.
View Our Latest Stock Analysis on Cencora
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
